{"id":"W2014639696","doi":"10.1097/mib.0000000000000218","title":"Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later","year":2014,"lang":"en","type":"review","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"","keywords":"Golimumab; Certolizumab pegol; Medicine; Infliximab; Adalimumab; Tumor necrosis factor alpha; Inflammatory bowel disease; Internal medicine; Food and drug administration; Crohn's disease; Clinical trial; Disease; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009499549,0.0007142199,0.001183641,0.001984269,0.0002210414,0.001198461,0.0004199268,0.001103114,0.00454864],"category_scores_gemma":[0.002484616,0.0002067989,0.001221665,0.001707874,0.0004756598,0.001143181,0.0006229589,0.002032224,0.002384632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001050372,"about_ca_system_score_gemma":0.001403039,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001804593,"about_ca_topic_score_gemma":0.003434712,"domain_scores_codex":[0.9994366,0.0001581574,0.00008601149,0.0001014697,0.0001657453,0.00005199645],"domain_scores_gemma":[0.999175,0.0004488855,0.0001085003,0.00002596738,0.0001917829,0.0000498618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005603399,0.000100297,0.0003428117,0.0202713,0.0003994988,0.000451322,0.00009913718,0.0002742878,0.001720155,0.006400872,0.04427837,0.9251016],"study_design_scores_gemma":[0.0001344896,0.0001633192,0.001304063,0.005461323,0.0003590876,0.001897636,0.00004866981,0.0000515824,0.0009381987,0.001333446,0.9882863,0.00002183501],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002384517,0.9968702,0.0001125964,0.0006135487,0.0005200148,0.00001158661,0.00003216615,0.000007974553,0.001593349],"genre_scores_gemma":[0.004509893,0.990245,0.0002151623,0.001476722,0.0004432948,0.00002692384,0.00008801273,0.000002397662,0.002992614],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00454864,"threshold_uncertainty_score":0.01521671,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01284495562256513,"score_gpt":0.274121509891346,"score_spread":0.2612765542687809,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}